抗人 NRARP 抗体对
01AB01535
NOTCH regulated ankyrin repeat protein (NRARP) is a small protein containing two ankyrin repeats that functions as a downstream effector and negative feedback regulator of Notch signaling. It plays a role in various developmental processes and is involved in the regulation of cell proliferation, differentiation, and apoptosis. NRARP stabilizes LEF1 protein, a key transcription factor in the Wnt signaling pathway, by blocking its ubiquitination. It is also involved in angiogenesis, acting downstream of Notch at branch points to regulate vascular density. NRARP expression has been found to be upregulated in several types of cancer, including non-small cell lung cancer (NSCLC), thyroid cancer, and breast cancer. High NRARP expression has been associated with poor prognosis in NSCLC patients and may serve as a potential biomarker for cancer progression. Downregulation of NRARP has shown antitumor activities in thyroid cancer cells.
| 规格 | 起售价 |
|---|---|
| 登录后可查看 | |
技术参数
- 靶点基因名
- NRARP
- 蛋白别名
- NOTCH regulated ankyrin repeat protein; NRARP
- UniProt
- Q7Z6K4
- 物种
- Human
产品详情
- 靶点名称
- NRARP
- 蛋白名称
- NOTCH regulated ankyrin repeat protein
- 蛋白别名
- Notch-regulated ankyrin repeat-containing protein
- 靶点基因名
- NRARP
- UniProt
- Q7Z6K4
- 来源物种
- Homo sapiens (Human)
- 物种反应性
- Human
背景介绍
NOTCH regulated ankyrin repeat protein (NRARP) is a small protein containing two ankyrin repeats that functions as a downstream effector and negative feedback regulator of Notch signaling. It plays a role in various developmental processes and is involved in the regulation of cell proliferation, differentiation, and apoptosis. NRARP stabilizes LEF1 protein, a key transcription factor in the Wnt signaling pathway, by blocking its ubiquitination. It is also involved in angiogenesis, acting downstream of Notch at branch points to regulate vascular density. NRARP expression has been found to be upregulated in several types of cancer, including non-small cell lung cancer (NSCLC), thyroid cancer, and breast cancer. High NRARP expression has been associated with poor prognosis in NSCLC patients and may serve as a potential biomarker for cancer progression. Downregulation of NRARP has shown antitumor activities in thyroid cancer cells.